Russell Z. Szmulewitz, MD

The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1152-1159.
PMID: 38236581

Bladder-Preserving Trimodality Therapy With Capecitabine.
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 Apr; 22(2):476-482.e1.
PMID: 38228414

Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and =75 Years: ARCHES Post Hoc Analysis.
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and =75 Years: ARCHES Post Hoc Analysis. Eur Urol Oncol. 2023 Dec 09.
PMID: 38072761

Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer.
Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer. Mol Cancer Ther. 2023 Nov 30.
PMID: 38030378

Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics.
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics. Molecules. 2023 Aug 13; 28(16).
PMID: 37630292

A usability and participatory design study for GeRI, an open-source, remote cancer treatment toxicity and frailty monitoring platform for older adults.
A usability and participatory design study for GeRI, an open-source, remote cancer treatment toxicity and frailty monitoring platform for older adults. J Geriatr Oncol. 2024 Jan; 15(1):101595.
PMID: 37487857

PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. Clin Cancer Res. 2023 05 15; 29(10):1929-1937.
PMID: 36897758

The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. Eur Urol. 2023 08; 84(2):229-241.
PMID: 37179240

SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis.
SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis. Cancer Lett. 2023 07 01; 565:216209.
PMID: 37169162

Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review.
Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review. Ther Adv Med Oncol. 2023; 15:17588359221149887.
PMID: 36743522

View All Publications